Loading…
← CockpitCompetitor Analysis › 1SXP.DE SCHOTT Pharma AG & Co. KGaAOpen in the cockpit ↗

SCHOTT Pharma AG & Co. KGaA1SXP.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Medical Specialties

German maker of glass and polymer packaging such as vials, syringes and cartridges used to package injectable drugs.

≈ A German West Pharmaceutical Services/Gerresheimer peerMomentum strong 74
Mkt cap
$3.73B
US dollars, full cap
Free float
18%
of shares outstanding
$/day
$2.45M
20-day average traded
Fwd P/E
23.0×
forward earnings
ROIC−WACC
+4.0 pp
WACC 7.4%
Hurdle
+2 pp
Req g minus delivered
Next earnings
22 days
10 Dec 2026
Close · EUR€22.60
1D+0.7%
1W+5.6%
1M-13.1%
3M-1.9%
6M+32.2%
YTD+49.7%
1Y+24.9%
ATR %3.4%
52w lowhigh13.7% off high

What SCHOTT Pharma AG & Co. KGaA does

German maker of glass and polymer packaging such as vials, syringes and cartridges used to package injectable drugs.

Sells vials, syringes and cartridges to drug makers in high volumes under supply agreements, as part of the approved drug's registered packaging, so changing supplier means re-approval and customers rarely switch. It is the pharmaceutical packaging arm of the SCHOTT glass group, which keeps the majority and listed it in 2023.

In one line: A German West Pharmaceutical Services/Gerresheimer peer.

Products and services

  • Glass vials
  • Prefillable syringes
  • Cartridges (e.g., for insulin/GLP-1 pens)
  • Polymer containment systems

Customers

  • Pharmaceutical & biotech companies (injectable dru

Where it sits in the supply chain

  • Materials
  • Pharma packaging
  • Glass & polymer drug-delivery packaging

What could go right

  • GLP-1/injectable drug packaging demand surge
  • Biologics/vaccine packaging growth

What could go wrong

  • Glass/energy input cost inflation
  • Customer destocking cycles

Moat: narrow (regulatory licence, customer qualification, process know-how). Pharma-grade glass/polymer manufacturing with long customer qualification cycles, benefiting from GLP-1/biologics packaging demand.

Headquarters: Mainz, Germany · Founded: 2020 · Employees: 4,811

Named competitors

SCHOTT Pharma AG & Co. KGaA at a glance

Size SCHOTT Pharma AG & Co. KGaA (1SXP.DE) is a Germany Health Care company (Medical Specialties) with a market value of $3.73B, the 81st largest of 198 Germany companies the cockpit tracks. Shares closed at €22.60 on 18 Nov 2026.

Performance Over six months the shares gained 32.2%, against +3.2% for the median peer and -0.9% for the Germany market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 4.3% over the last twelve months (peer median +7.4%); the operating margin is 15.5% (peer median 11.6%).

Valuation It trades at 23.0× forward earnings against a peer median of 24.4× (10th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.0 points above its cost of capital (7.4% WACC).

Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 20261SXP.DE 129Peer median 105
Six months, rebased to 100: SCHOTT Pharma AG & Co. KGaA against the median of its 20 peers (local-currency closes).

SCHOTT Pharma AG & Co. KGaA financials

Reported figures in EUR; fiscal year ends 2025-09-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€1.02B€986M€957M€899M€821M
Revenue growth—+3%+7%+9%—
Gross profit€317M€332M€323M€315M€295M
EBITDA€245M€255M€238M€211M€217M
Net income€137M€146M€150M€152M€125M
Free cash flow€55.3M€35.6M€79.7M€6.18M€30.1M
Capital expenditure€138M€145M€145M€176M€153M
Total debt€0€83.0M€85.8M€72.3M€74.8M

Quarterly statements and history in the cockpit →

SCHOTT Pharma AG & Co. KGaA competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%NVST603014002432TECNCDNAFIE4203AMBU-BAXGNPLSE603658TMDX002223STVN688301603301300003IRTCAFXICUI1SXP.DE6-month return →1-month return →
Up and to the right = strong over both horizons. SCHOTT Pharma AG & Co. KGaA is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%25×50×75×100×NVST603014002432TECNCDNAFIE4203AMBU-BAXGNTMDX688301603301300003IRTCICUI1SXP.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SCHOTT Pharma AG & Co. KGaA is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%NVST603014002432TECNFIEAMBU-BAXGNTMDX603301300003IRTCICUI1SXP.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SCHOTT Pharma AG & Co. KGaA is the large dot.

SCHOTT Pharma AG & Co. KGaA competitors and peer comparison

Head to head with its named competitors (1SXP.DE vs GXI.DE vs WST vs GLW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
SCHOTT Pharma AG & Co. KGaA 1SXP.DE$3.73B+32%+4%15%23.0×12.7%
Gerresheimer GXI.DE$1.26B+21%+9%-4%16.0×57.0%
West Pharmaceutical Services WST$28.1B+32%+13%23%40.2×25.8%
Corning GLW$93.2B-40%+19%17%25.7×25.6%

How SCHOTT Pharma AG & Co. KGaA compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SCHOTT Pharma AG & Co. KGaA against its 20 peers (data as of 18 Nov 2026)
Measure1SXP.DEPeer medianRank in peer set
1-month return-13.1%+5.3%4th lowest of 21
6-month return+32.2%+3.2%7th highest of 21
Distance from 52-week high-13.7%-24.1%6th highest of 21
Revenue growth (TTM)+4.3%+7.4%10th lowest of 21
Operating margin15.5%11.6%4th highest of 20
Forward P/E23.0×24.4×10th cheapest of 20
Growth the price implies (Req g, 7 yrs)12.7%10.0%8th most demanding of 18
Growth delivered (Del g)+11.0%+8.9%7th highest of 18
Hurdle (Req g minus delivered)+1.6 pp+1.0 pp8th most demanding of 18
ROIC minus cost of capital+4.0 pp-1.1 pp4th highest of 19
EV / EBITDA13.8×13.3×6th cheapest of 11
Net debt / EBITDA-0.1×1.1×4th least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%

Questions

Who are SCHOTT Pharma AG & Co. KGaA's main competitors?
Named competitors: Gerresheimer (GXI.DE), West Pharmaceutical Services (WST), Corning (GLW). The cockpit's measured peer set (industry) also includes Envista (NVST), Shandong Weigao Blood Purification Products (603014.SS), Andon Health (002432.SZ), Tecan (TECN.SW), CareDx (CDNA), Fielmann (FIE.DE).
Is SCHOTT Pharma AG & Co. KGaA expensive compared with its peers?
On forward p/e it trades at 23.0× against a peer median of 24.4×, 10th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has SCHOTT Pharma AG & Co. KGaA stock performed?
Over six months to 18 Nov 2026 the shares returned +32.2% against +3.2% for the median peer; over one year +24.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.